STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows

CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer. 

The results reported Saturday from the randomized Phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed, metastatic, triple-negative breast cancer, experts said. 

Gilead, which conducted the study, could also benefit from a boost in Trodelvy sales at a time when it faces competition from a similar drug made by AstraZeneca and Daiichi Sankyo.

Continue to STAT+ to read the full story…